The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ALIGOS THERAPEUTICS INC | COM | 01626L105 | 555,182 | 743,215 | SH | DFND | 1 | 0 | 743,215 | 0 | ||
| ARCUTIS BIOTHERAPEUTICS INC | COM | 03969K108 | 5,869,191 | 1,105,309 | SH | DFND | 1 | 0 | 1,105,309 | 0 | ||
| BOLT BIOTHERAPEUTICS INC | COM | 097702104 | 1,967,126 | 1,891,467 | SH | DFND | 1 | 0 | 1,891,467 | 0 | ||
| EXSCIENTIA PLC | ADS | 30223G102 | 3,482,660 | 770,500 | SH | DFND | 1 | 0 | 770,500 | 0 | ||
| FUSION PHARMACEUTICALS INC | COM | 36118A100 | 4,058,553 | 1,560,982 | SH | DFND | 1 | 0 | 1,560,982 | 0 | ||
| GRACELL BIOTECHNOLOGIES INC | SPONSORED ADS | 38406L103 | 3,960,000 | 1,375,000 | SH | DFND | 1 | 0 | 1,375,000 | 0 | ||
| INOZYME PHARMA INC | COM | 45790W108 | 18,878,374 | 4,494,851 | SH | DFND | 1 | 0 | 4,494,851 | 0 | ||
| IO BIOTECH INC | COM | 449778109 | 1,218,518 | 864,197 | SH | DFND | 1 | 0 | 864,197 | 0 | ||
| KARUNA THERAPEUTICS INC | COM | 48576A100 | 134,766,083 | 797,008 | SH | DFND | 1 | 0 | 797,008 | 0 | ||
| OCULIS HOLDING AG | ORDINARY SHARES | H5870P102 | 24,406,294 | 2,218,754 | SH | DFND | 1 | 0 | 2,218,754 | 0 | ||
| RALLYBIO CORP | COM | 75120L100 | 8,103,650 | 2,404,644 | SH | DFND | 1 | 0 | 2,404,644 | 0 | ||
| VAXCYTE INC | COM | 92243G108 | 40,429,128 | 793,036 | SH | DFND | 1 | 0 | 793,036 | 0 | ||
| VIGIL NEUROSCIENCE INC | COM | 92673K108 | 3,021,607 | 560,595 | SH | DFND | 1 | 0 | 560,595 | 0 | ||